Skip to main
University-wide Navigation

10th Annual Sanders-Brown Markesbery Symposium on Aging and Dementia Taking Place Virtually

In the sessions for both the scientific and community audience, attendees will have the opportunity to hear clinicians and researchers from UK and other institutions share current findings, trends, and latest updates on dementia and aging disorders.

Call for Abstracts/Posters for Markesbery Scientific Symposium & Poster Session

You are invited to submit an abstract and participate in the virtual poster session held in conjunction with the annual Markesbery Scientific Symposium on Monday, November 9, 2020. The poster session will be held from 11:00 am – 12:50 pm with awards announced at 12:55 pm. The poster competition is for outstanding work by graduate students and postdocs. Judged poster awards will be limited to trainees. The student/postdoc MUST be the first author and submit the abstract under his/her name. Abstract Preparation Instructions

Sanders-Brown Research Discovers New Pathway in TDP-43 Related Dementias

Selenica says their study is the first to provide a novel pathway and identify potential therapeutic targets for TDP-43 proteinopathies – especially in Alzheimer’s disease and the newly characterized form of dementia known as LATE.

Sanders-Brown Study Leads to Potential New Treatment Approach for Alzheimer’s Disease

Through the group's work, they found that the therapeutic targeting of TREM2 using a TREM2-activating antibody leads to the activation of microglia, recruitment of microglia to amyloid plaques, reduced amyloid deposition, and ultimately improved cognition.

UK’s Sanders-Brown, Penn Researchers Provide Insights into Newly Characterized Form of Dementia

“We used to think that aging-related memory and thinking decline meant one thing: a disease called Alzheimer’s disease. Now we know that the disease we were calling Alzheimer’s disease is actually many different conditions, often in combination."

Important Dementia Studies Continuing at UK Despite Ongoing COVID-19 Pandemic

Researchers will be looking at a medication that recently received experimental approval from the USDA and its impact on the newly characterized form of dementia known as LATE. LATE is a disease with symptoms similar to Alzheimer’s disease.

Researchers Publish Study Looking at Approaches to Better Treat Alzheimer's Disease

For the past several decades, much of the work to find a treatment for AD has been focused on eliminating those dreaded Aβ plaques, by assuming that memory could be restored by removing the plaques.

UK Sanders-Brown Center on Aging Facilitates First Participant in Worldwide Drug Study

This work is looking at a study medication, BAN2401, to determine if it can help prevent worsening memory and thinking among individuals who might be at risk for future decline. They are hoping it will ultimately help prevent Alzheimer’s disease.

Sanders-Brown Researcher Receives Grant Supported by Rotary Clubs to Further Dementia Studies

The $125,000 grant comes from The CART Fund. CART (Coins for Alzheimer’s Research Trust) is a grassroots effort by Rotary Club members throughout the country to provide cutting edge research to help find a cure for Alzheimer’s.

It’s Not Just Alzheimer’s Disease: Sanders-Brown Research Highlights Form of Severe Dementia

The long-running study on aging and brain health at UK’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.